S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:AUGX

Augmedix (AUGX) Stock Price, News & Analysis

$4.09
+0.05 (+1.24%)
(As of 03/28/2024 ET)
Today's Range
$3.93
$4.16
50-Day Range
$3.20
$5.04
52-Week Range
$1.50
$6.25
Volume
228,282 shs
Average Volume
389,867 shs
Market Capitalization
$169.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.83

Augmedix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.1% Upside
$6.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to ($0.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

AUGX stock logo

About Augmedix Stock (OTCMKTS:AUGX)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

AUGX Stock Price History

AUGX Stock News Headlines

Augmedix (OTCMKTS:AUGX) Trading Up 1%
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Benchmark Co. Keeps Their Buy Rating on Augmedix (AUGX)
AUGX Mar 2024 7.500 call
AUGX Apr 2024 5.000 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Augmedix Inc
Augmedix, Inc. (AUGX)
Why Is Augmedix (AUGX) Stock Down 27% Today?
See More Headlines
Receive AUGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
Current Symbol
OTCMKTS:AUGX
Fax
N/A
Employees
1,040
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.83
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+67.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-24,450,000.00
Pretax Margin
-57.23%

Debt

Sales & Book Value

Annual Sales
$40.93 million
Book Value
$0.10 per share

Miscellaneous

Free Float
36,316,000
Market Cap
$169.18 million
Optionable
Not Optionable
Beta
-0.14
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Emmanuel Krakaris (Age 65)
    President, CEO, Secretary & Director
    Comp: $734.33k
  • Mr. Ian Shakil (Age 39)
    Founder, Chief Strategy Officer & Director
  • Ms. Sandra Breber (Age 66)
    Chief Operating Officer
    Comp: $446.05k
  • Mr. Saurav Chatterjee Ph.D. (Age 52)
    Chief Technology Officer
    Comp: $438.05k
  • Mr. Paul Louis Ginocchio (Age 54)
    Chief Financial Officer
  • Todd Holvick
    Head of Legal & Compliance
  • Lia Wallick
    Head of People
  • Dr. Davin Lundquist M.D.
    Chief Medical Officer
  • Mr. Jonathan Hawkins (Age 54)
    Chief Revenue Officer
    Comp: $417.71k
  • Mr. Tomer Levy
    Senior Vice President of Engineering

AUGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Augmedix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUGX shares.
View AUGX analyst ratings
or view top-rated stocks.

What is Augmedix's stock price target for 2024?

3 brokerages have issued 12 month target prices for Augmedix's stock. Their AUGX share price targets range from $6.00 to $8.00. On average, they predict the company's share price to reach $6.83 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for AUGX
or view top-rated stocks among Wall Street analysts.

How have AUGX shares performed in 2024?

Augmedix's stock was trading at $5.85 at the start of the year. Since then, AUGX stock has decreased by 30.1% and is now trading at $4.09.
View the best growth stocks for 2024 here
.

How were Augmedix's earnings last quarter?

Augmedix, Inc. (OTCMKTS:AUGX) posted its quarterly earnings data on Monday, March, 27th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The firm earned $8.75 million during the quarter, compared to analyst estimates of $8.52 million. Augmedix had a negative trailing twelve-month return on equity of 980.09% and a negative net margin of 57.70%.

How do I buy shares of Augmedix?

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:AUGX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners